Back to search

Article

BRCA2 reversion mutations as a resistance mechanism to olaparib in patients with BRCA2-mutated mCRPC: A Case Series

2026-02-02

Abstract excerpt

<title>Abstract</title> <p> <bold>Background:</bold> Prostate cancer with <italic>BRCA2</italic> mutations has shown sensitivity to poly (ADP-ribose) polymerase (PARP) inhibitors such as olaparib. However, acquired resistance remains a clinical concern. One potential mechanism of resistance is the emergence of reversion mutations that restore the function of BRCA2. Although this mechanism has been observed in...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
11c6d993-c37e-5feb-87cd-335dd65218b1
DOI
10.21203/rs.3.rs-8249251/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
BRCA2 reversion mutations as a resistance mechanism to olaparib in patients with BRCA2-mutated mCRPC: A Case SeriesDOI 10.21203/rs.3.rs-8249251/v1
Acquired Resistance to Poly (ADP-ribose) Polymerase Inhibitor Olaparib in BRCA2-Associated Prostate Cancer Resulting From Biallelic BRCA2 Reversion Mutations Restores Both Germline and Somatic Loss-of-Function MutationsSemantic proximity
Emergence of polyclonal BRCA2 reversions following PARP inhibitor treatment: An illustrative case report.Semantic proximity
BRCA1/2 Reversion Mutations in Patients Treated with Poly ADP-Ribose Polymerase (PARP) Inhibitors or Platinum Agents.Semantic proximity
Convergent evolution of BRCA2 reversion mutations under therapeutic pressure by PARP inhibition and platinum chemotherapySemantic proximity
Polyclonal BRCA2 mutations following carboplatin treatment confer resistance to the PARP inhibitor rucaparib in a patient with mCRPC: a case reportSemantic proximity
Emergence of BRCA Reversion Mutations in Prostate Cancer Prior to PARP Inhibitor Exposure: Clinical and Therapeutic Implications.Semantic proximity
Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib.Semantic proximity
Treatment-emergent neuroendocrine prostate cancer with a germline BRCA2 mutation: identification of a candidate reversion mutation associated with platinum/PARP-inhibitor resistance.Semantic proximity
Genomic Profiling in ctDNA Revealing Complicated Resistance Mechanism of Olaparib and Abiraterone as Salvage Therapy in Prostate Cancer: A Case ReportSemantic proximity
Metastatic lung adenocarcinoma with BRCA2 mutation and longstanding disease control on olaparib, developing triple negative breast adenocarcinoma with additional BRCA2 reversion mutation: a case report.Semantic proximity
Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP InhibitorsSemantic proximity
Elucidating acquired PARP inhibitor resistance in advanced prostate cancer.Semantic proximity
Select a neighboring publication to make it the new centre.